Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

被引：13

作者：

Zaja, Francesco ^{[1
,2
]}

Salvi, Flavia ^{[3
]}

Rossi, Maura ^{[4
]}

Sabattini, Elena ^{[5
]}

Evangelista, Andrea ^{[5
]}

Ciccone, Giovannino ^{[6
,7
]}

Angelucci, Emanuele ^{[8
]}

Gaidano, Gianluca ^{[9
]}

Zanni, Manuela ^{[9
]}

Ladetto, Marco ^{[3
]}

Chiappella, Annalisa ^{[10
]}

Vitolo, Umberto ^{[10
]}

Zinzani, Pier Luigi ^{[11
]}

Califano, Catello ^{[12
]}

Tucci, Alessandra ^{[13
,14
]}

Patti, Caterina ^{[15
]}

Pileri, Stefano A. ^{[16
]}

Lenti, Valentina ^{[17
]}

Piccaluga, Pier Paolo ^{[4
]}

Cavallo, Federica ^{[18
]}

Volpetti, Stefano ^{[19
,20
]}

Perali, Giulia ^{[19
,20
]}

Assouline, Sarit ^{[21
]}

Mann, Koren Kathleen ^{[22
]}

Morin, Ryan ^{[23
]}

Alcaide, Miguel ^{[23
]}

Bushell, Kevin ^{[23
]}

Fanin, Renato ^{[1
,2
]}

Levis, Alessandro ^{[17
]}

机构：

[1] Univ Udine, Clin Ematol, DAME, Udine, Italy

[2] Univ Udine, Unita Terapie Cellulari Carlo Melzi, DAME, Udine, Italy

[3] AO SS Antonio & Biagio & C Arrigo, SC Ematol, Alessandria, Italy

[4] Univ Hosp Bologna, Unit Haemolymphopathol, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[5] Univ Hosp Bologna, Dept Hematol & Oncol, Unit Haemolymphopathol, Bologna, Italy

[6] AOU Citta Salute & Sci Torino, Unit Clin Epidemiol, Turin, Italy

[7] CPO Piemonte, Turin, Italy

[8] IRCCS AOU San Martino IST, UOC Ematol, Genoa, Italy

[9] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy

[10] AOU Citta Salute & Sci, SC Ematol, Turin, Italy

[11] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[12] Osped Umberto I, UO Med Oncoematol, Nocera Inferiore, Italy

[13] Spedali Civil Brescia, SC Ematol, Brescia, Italy

[14] Spedali Civil Brescia, Dipartimento Oncol Med, Brescia, Italy

[15] Osped V Cervello, UOC Ematol, Palermo, Italy

[16] Milano Univ, Sch Med, European Inst Oncol, Haematopathol Unit, Bologna, Italy

[17] Fdn Italiana Linfomi, Alessandria, Italy

[18] Univ Torino, Azienda Osped Univ Citta Salute & Sci, Turin, Italy

[19] Azienda Sanit Univ Integrata, Clin Ematol, Udine, Italy

[20] Azienda Sanit Univ Integrata, Unita Terapie Cellulari Carlo Melzi, Udine, Italy

[21] McGill Univ, Jewish Gen Hosp, Div Hematol, Montreal, PQ, Canada

[22] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada

[23] Simon Fraser Univ, Dept Mol Biol & Biochem, Sch Comp Sci, Vancouver, BC, Canada

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 12期

关键词：

Diffuse large B-cell lymphoma; panobinostat; relapsed/refractory; genomic; DEACETYLASE INHIBITOR PANOBINOSTAT; HISTONE DEACETYLASES; RITUXIMAB; DISEASE; MULTICENTER; ROMIDEPSIN; MUTATION; LBH589; TRIAL; CHOP;

D O I：

10.1080/10428194.2018.1452208

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

引用

页码：2904 / 2910

页数：7

共 50 条

[41] Late Toxicities and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Series of Systematic Reviews of the Fondazione Italiana Linfomi
Minoia, Carla
Gerardi, Chiara
Allocati, Eleonora
De Sanctis, Vitaliana
Franceschetti, Silvia
Viviani, Simonetta
Annunziata, Maria Antonietta
Bari, Alessia
Skrypeta, Tetiana
Oliva, Stefano
Puzzovivo, Agata
Di Molfetta, Sergio
Caccavari, Valentina
Di Russo, Anna
Loseto, Giacomo
Daniele, Antonella
Nassi, Luca
Gini, Guido
Guarini, Attilio
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S374 - S375
[42] Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi
Ballotta, Laura
Zinzani, Pier Luigi
Pileri, Stefano
Bruna, Riccardo
Tani, Monica
Casadei, Beatrice
Tabanelli, Valentina
Volpetti, Stefano
Luminari, Stefano
Corradini, Paolo
Lucchini, Elisa
Tisi, Maria Chiara
Merli, Michele
Re, Alessandro
Varettoni, Marzia
Pesce, Emanuela Anna
Zaja, Francesco
FRONTIERS IN ONCOLOGY, 2021, 11
[43] Single Agent Ofatumumab In Patients With Relapsed and/Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results From a Phase II Open Label Study
Jasielec, Jagoda
Peace, David
Edwards, Sarah
Tolzien, Kathy
Smith, Sonali M.
Nabhan, Chadi
BLOOD, 2013, 122 (21)
[44] A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Kambhampati, Swetha
Kallam, Avyakta
Borogovac, Azra
Chen, Lu
Puverel, Sandrine
Johnson, Jennifer
Melgar, Ivana
Baird, John H.
Danilov, Alexey
Godfrey, James
Khan, Niloufer
Mei, Matthew
Phillips, Tycel J. J.
Siddiqi, Tanya
Shouse, Geoffrey
Zain, Jasmine
Kwak, Larry W.
Rosen, Steven T.
Forman, Stephen J.
Song, Joo Y.
Herrera, Alex F.
Budde, Elizabeth
BLOOD, 2024, 144 : 17421 - 17422
[45] Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials
Brault, Marion
Annereau, Maxime
Danu, Alina
Lazarovici, Julien
Chahine, Claude
Varga, Andrea
Baldini, Capucine
Champiat, Stephane
Berhoune, Malik
Massard, Christophe
Lemare, Francois
Ribrag, Vincent
Michot, Jean-Marie
BLOOD, 2018, 132
[46] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Ren, Liangliang
Li, Ling
Zhang, Lei
Li, Xin
Fu, Xiaorui
Wang, Xinhua
Wu, Jingjing
Sun, Zhenchang
Feng, Xiaoyan
Chang, Yu
Zhou, Zhiyuan
Nan, Feifei
Yan, Jiaqin
Kong, Fei
Zhang, Mingzhi
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (01) : 42 - 50
[47] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Liangliang Ren
Ling Li
Lei Zhang
Xin Li
Xiaorui Fu
Xinhua Wang
Jingjing Wu
Zhenchang Sun
Xiaoyan Feng
Yu Chang
Zhiyuan Zhou
Feifei Nan
Jiaqin Yan
Fei Kong
Mingzhi Zhang
Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 42 - 50
[48] Copanlisib in Combination with Rituximab and Bendamustine for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: Results from the Phase II Multicenter Fil_Copa-Rb Trial from Fondazione Italiana Linfomi (FIL)
Frascione, Pio Manlio Mirko
Novo, Mattia
Castellino, Alessia
Marcheselli, Luigi
Dattoli, Samantha Deianira
Tucci, Alessandra
Gini, Guido
Tarantini, Giuseppe
Mannina, Donato
Arcari, Annalisa
Martiniani, Roberta
Scarpa, Elisabetta
Marino, Dario
Spina, Michele
Gorgone, Ausilia Giuseppa
Di Renzo, Nicola
Mancuso, Salvatrice
Petrucci, Luigi
Tafuri, Agostino
Vitolo, Umberto
BLOOD, 2023, 142
[49] Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase II Study
Bennani, N. Nora
Atherton, Pamela
Steinert, Kimberly O.
Rimsza, Lisa M.
Tun, Aung M.
Hoffmann, Marc S.
Narkhede, Mayur S.
Vaidya, Rakhee
Said, Rabih
Shapiro, Geoffrey I.
Costello, Brian A.
Ansell, Stephen M.
Nowakowski, Grzegorz S.
BLOOD, 2023, 142
[50] SUBGROUP ANALYSES OF DIFFUSE LARGE B-CELL LYMPHOMA AND INDOLENT LYMPHOMA COHORTS FROM A PHASE IIA STUDY OF SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
Jurczak, W.
Zinzani, P. L.
Gaidano, G.
Goy, A.
Provencio, M.
Nagy, Z.
Robak, T.
Maddocks, K.
Buske, C.
Ambarkhane, S.
Winderlich, M.
Endell, J.
Blum, K.
HAEMATOLOGICA, 2016, 101 : 317 - 317

← 1 2 3 4 5 →